A test tube marked vaccine is shown in front of the AstraZeneca logo in this illustration taken September 9, 2020.
Dado Ruvic | Reuters
LONDON – The British pharmaceutical giant AstraZeneca said on Monday that the potential Covid-1
Side effects of the vaccine among the elderly – the age group with the highest risk from coronavirus – were also found to be lower, said AstraZeneca. The drug manufacturer's potential Covid-19 vaccine is being developed in collaboration with the University of Oxford.
The announcement is likely to increase hopes that a Covid vaccine will be developed before the end of the year.
"It is encouraging to see that the immunogenicity responses were similar between older and younger adults, and that the reactogenicity was lower in older adults, where the severity of COVID-19 is higher," an AstraZeneca spokesman told CNBC via email.
"The results further build the body of evidence for the safety and immunogenicity of AZD1222," the spokesman said, referring to the technical name of the Oxford-AstraZeneca vaccine.
The shares in the company rose around 0.8% in the news. a safe and effective vaccine in an effort to end the coronavirus pandemic that has claimed over 1.15 million lives.
Dozens of candidate vaccines are in clinical evaluation, according to the World Health Organization, with some already conducting late-stage trials before applying for formal approval.
The vaccine, developed by the University of Oxford and AstraZeneca, is believed to be one of the frontrunners in securing regulatory approval.
AstraZeneca CEO Pascal Soirot has previously said that the drug manufacturer's vaccine is likely to provide protection against coronavirus for about a year.